The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: The Veterans Affairs Diabetes Trial previously showed that intensive glucose lowering, as compared with standard therapy, did not significantly reduce the rate of major cardiovascular events among 1791 military veterans (median follow-up, 5.6 years). We report the extended follow-up of the study participants. METHODS: After the conclusion of the clinical trial, we followed participants, using central databases to identify procedures, hospitalizations, and deaths (complete cohort, with follow-up data for 92.4% of participants). Most participants agreed to additional data collection by means of annual surveys and periodic chart reviews (survey cohort, with 77.7% follow-up). The primary outcome was the time to the first major cardiovascular event (heart attack, stroke, new or worsening congestive heart failure, amputation for ischemic gangrene, or cardiovascular-related death). Secondary outcomes were cardiovascular mortality and all-cause mortality. RESULTS: The difference in glycated hemoglobin levels between the intensive-therapy group and the standard-therapy group averaged 1.5 percentage points during the trial (median level, 6.9% vs. 8.4%) and declined to 0.2 to 0.3 percentage points by 3 years after the trial ended. Over a median follow-up of 9.8 years, the intensive-therapy group had a significantly lower risk of the primary outcome than did the standard-therapy group (hazard ratio, 0.83; 95% confidence interval [CI], 0.70 to 0.99; P=0.04), with an absolute reduction in risk of 8.6 major cardiovascular events per 1000 person-years, but did not have reduced cardiovascular mortality (hazard ratio, 0.88; 95% CI, 0.64 to 1.20; P=0.42). No reduction in total mortality was evident (hazard ratio in the intensive-therapy group, 1.05; 95% CI, 0.89 to 1.25; P=0.54; median follow-up, 11.8 years). CONCLUSIONS: After nearly 10 years of follow-up, patients with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had 8.6 fewer major cardiovascular events per 1000 person-years than those assigned to standard therapy, but no improvement was seen in the rate of overall survival. (Funded by the VA Cooperative Studies Program and others; VADT ClinicalTrials.gov number, NCT00032487.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Post-trial observational follow-up of the VADT over 10 years has also shown a significant reduction in the primary outcome of major CVD events, with myocardial infarctions and heart failure being the most common outcomes (60).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [60]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, during an observational median follow up of 9.8 years, the intensive-therapy group had a significantly lower risk of the primary outcome (MI, stroke, new or worsening congestive heart failure [CHF], amputation for ischemic gangrene, or CV-related death) than did the standard therapy group (HR 0.83, p=0.04), with an absolute reduction in risk of 8.6 major CV events per 1,000 personyears (”
From Targets for Glycemic Control (2018) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, longer-term epidemiological follow-up of these studies also showed a pattern of CVD benefit (58-60).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [60]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In people with type 2 diabetes and established, or very high risk for, cardiovascular disease (CVD), there is a clear association between an increased mortality and severe hypoglycemia (62,63) and symptomatic hypoglycemia (64).”
From Hypoglycemia (2018) · cites this paper as [62]
Experimental — accuracy not yet measured
In the citing paper
“Meta-analyses have clearly shown that tight blood glucose control leads to the suppression of ASCVD incidence795, 796).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [795]
In the citing paper
“However, 10-year follow-up of the VADT cohort (64) did demonstrate a reduction in the risk of cardiovascular events (52.7 [control group] vs. 44.1 [intervention group] events per 1,000 person-years) with no benefit in cardiovascular or overall mortality.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [64]
In the citing paper
“However, 10-year follow-up of the VADT cohort (64) did demonstrate a reduction in the risk of cardiovascular events (52.7 [control group] vs. 44.1 [intervention group] events per 1,000 person-years) with no benefit in cardiovascular or overall mortality.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [64]
In the citing paper
“However, 10-year follow-up of the VADT cohort (64) did demonstrate a reduction in the risk of cardiovascular events (52.7 [control group] vs. 44.1 [intervention group] events per 1,000 person-years) with no benefit in cardiovascular or overall mortality.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [64]
In the citing paper
“In all three trials, severe hypoglycemia was significantly more likely in participants who were randomly assigned to the intensive glycemic control arm.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Self-citationMeta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Flagged first, then by citations
Research works printed but not linked: 1
- Hayward RA, 2007, Am J Manag Care, 13, 126
Cited by
Sorted by citations
Items 501–600 of 667
Bordier, L., Sollier, M., Dolz, M., Garcia, C., Allain, J., & Bauduceau, B. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30022-7 · Cited by 3
Diabète de type 2 : les médicaments hypoglycémiants et leurs risques cardiovasculaires
Bauduceau, B., & Bordier, L. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30390-5 · Cited by 2
Zhang, X., Nie, M., Chen, X., Liang, Z., & Zhao, Q. (2021) · Journal of Interventional Cardiology · doi:10.1155/2021/5565987 · Cited by 2
Glycemic Index and Diabetes Mellitus
(2016) · CRC Press eBooks · doi:10.1201/9781315371764-5 · Cited by 2
Félix-Redondo, F. J., Lozano, L., Consuegra‐Sánchez, L., Sáez, F. G., de Vargas, F. J. G., Castellano, J. M., & Fernandez-Berges, D. J. (2016) · Open Heart · doi:10.1136/openhrt-2015-000368 · Cited by 2
“2% of known patients with diabetes were being treated with drugs, and less than one-third had their baseline blood glucose controlled, although the cardiovascular benefit of strict control of glycaemia in these patients is not clear.(19) Active tobacco use after the coronary event was very rare in women (2.”
BackgroundHirai, K., Imamura, S., Ookawara, S., Hirai, A., & Morishita, Y. (2017) · Nephro-Urology Monthly · doi:10.5812/numonthly.55058 · Cited by 2
Rajendran, J., Srinivasan, A. R., & Maran, A. L. (2019) · Europe PMC (PubMed Central) · Cited by 2
Pineda, C. L. F., Suárez, F. C., Ochoa, A., Rengifo-Quintero, L. J., & Isaza, J. R. (2018) · Acta Médica Colombiana · doi:10.36104/amc.2018.970 · Cited by 2
Management of cardiovascular risk at patients with a diabetes mellitus type 2.
Владимировна, П. А., Verbovoy, A. F., Galkin, R. A., Verbovaya, N. I., Sharonova, L. A., & Dolgikh, Y. A. (2018) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2018-96-8-696-701 · Cited by 2
Insulin Pumps and Artificial Pancreas
Taleb, N., Gingras, V., & RABASA-LHORET, R. P. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65407-7 · Cited by 3
Hu, X., Li, W., Wang, C., Zhang, H., Lu, H., Li, G., Zhou, Y., & Dong, H. (2021) · Research Square · doi:10.21203/rs.3.rs-724546/v1 · Cited by 2
Serum Magnesium Level Change in Type 2 Diabetic Patients with Cardiovascular Complications
ELGAZZAR, M. S. E. T. E. M., & AMAL SAID ALBENDARY, M. D. ;. Y. M. A. (2019) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2019.59517 · Cited by 1
Shao, H., Laxy, M., Gregg, E. W., Albright, A. L., & Zhang, P. (2020) · Value in Health · doi:10.1016/j.jval.2020.09.010 · Cited by 1
Ishtiaque, A., Khan, S. M., Azhar, S., Mehmood, M., & Shahnawaz, S. (2022) · doi:10.53350/pjmhs221610459 · Cited by 1
Optimizing Type 2 Diabetes Management: The Efficacy and Safety of Gliclazide in Clinical Practice
Mohan, V., Makkar, B. M., Saboo, B., Jagadisha, A., Chawla, M. S., Deshpande, N., Goyal, V. K., & Kapoor, R. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_50_25 · Cited by 1
Deshmukh, A. P., Tiwari, A. V., Tiwari, S. P., Yawale, D. S., Deshmukh, D. P., Dixit, M. S., & Yawale, S. P. (2025) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2025.100712 · Cited by 1
Metabolic memory failure and the reprogramming of atherosclerosis in diabetes
Devi, M., Sukumaran, E. S., Harikrishnan, N., Pavithra, N., & Shakthi, L. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100703 · Cited by 1
Valencia, I., Vidal‐Gómez, X., Hipólito‐Luengo, Á. S., Villacampa, A., Shamoon, L., Cuadrado-Gómez, A., Berlanas-Vicente, D., de la Cuesta, F., Moncada, S., Gómez-Cerezo, J. F., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118180 · Cited by 3
Bloomgarden, Z. T. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.02.001 · Cited by 1
Kardiovaskuläre Erkrankungen bei Diabetes mellitus
Saely, C. H., Vathie, K., & Drexel, H. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0080-y · Cited by 1
“Ein ähnlicher Effekt wurde in der ADVANCE-Studie nicht beobachtet [40], während im VADT, ähnlich wie in der UKPDS, eine signifikante Reduktion makrovaskulärer Ereignisse in derNachbeobachtung bei jenen Patienten auffiel, die während der Studie in die Gruppe mit aggressiverer Glukosesenkung randomisiert gewesen waren […”
BackgroundGlucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?
Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2016) · Endocrine · doi:10.1007/s12020-016-0981-y · Cited by 1
Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
Ganda, O. P. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83.s1.03 · Cited by 1
Kardiovaskuläre Effekte der Insulintherapie
Pfohl, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0088-3 · Cited by 1
“In den 3 großen Langzeitstudien zur intensivenBlutzuckerkontrolle beiTyp-2-Diabetes – ACCORD, ADVANCE („action in diabetes and vascular disease: preterax and diamicron MR controlled evaluation“) und VADT („veterans affairs diabetes trial“) – lag die Hypoglykämierate in den intensiv eingestellten Patientengruppen deutl…”
BackgroundIs diabetes still a state of premature cardiovascular death?
Fisher, M. (2016) · Practical Diabetes · doi:10.1002/pdi.2057 · Cited by 1
Vegetarian Diets in People With Type 2 Diabetes
Kahleová, H., & Pelikánová, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803968-7.00021-6 · Cited by 1
Glycemic targets in patients with diabetes
Jeon, J. Y., & Kim, D. J. (2017) · Journal of Korean Medical Association · doi:10.5124/jkma.2017.60.11.889 · Cited by 1
Stratégie thérapeutique dans le traitement du diabète de type 2
Bauduceau, B., & Bordier, L. (2018) · Time to knit · doi:10.1016/s1155-1941(18)82762-7 · Cited by 1
Primary and Secondary Prevention of Cardiovascular Disease
Bader, B., & Schwartz, R. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-89725-7_4 · Cited by 1
Facteurs de risque et maladies chroniques : le diabète en exemple
Schlienger, J.-L., Monnier, L., Essekkat, N., Azrak, A. E., Raji, F., & Rochd, D. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30019-7 · Cited by 2
Les troubles cognitifs chez les patients diabétiques âgés. Apport de l’étude Gérodiab
Bauduceau, B., Bordier, L., Floch, J. P. L., Verny, C., & Doucet, J. (2016) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30679-x · Cited by 1
Gravicentric approach to Type 2 Diabetes therapy. The success prediction. A proof-of-concept
Levit, S., Torban, N., Boaz, M., Weichman, M., Azuri, J., Manisterski, Y., Merzon, E., Ryder, D., Ginossar, G., Gavra, T., et al. (2020) · Pharmacy Formulas · doi:10.17816/phf34728 · Cited by 1
Glycemic Control and Future Perspectives for Treatment
Miyamoto, S., & Shikata, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-9301-7_6 · Cited by 1
The First Case of Free Radial Forearm Skin Flap: A 40-Year Follow-Up Study
Wang, H., Guo, B., Hui, Q., Jiang, D., Liu, X., & Tao, K. X. (2020) · Chinese Journal of Plastic and Reconstructive Surgery · doi:10.1016/s2096-6911(21)00032-7 · Cited by 1
Principles of Diabetes Care and Lifestyle Modification
Moon, M. K. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_8 · Cited by 3
Pharmacotherapy follow-up in elderly in a public outpatient clinic in Brasilia, Brazil
Mirna, P. F. O., & Novaes, M. R. C. G. (2015) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp2015.4399 · Cited by 1
“Moreover, it has shown to decrease health assistance costs, fostering improvement of the patient’s quality of life altogether (Aguiar et al., 2012; Balisa-Rocha et al., 2014; Castro et al., 2006; Chisholm-Burns et al., 2010; Correr et al., 2011; Hayward et al., 2015; Lyra Jr et al., 2008; Mansoor et al., 2014; Morgado…”
BackgroundInfluentialSGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease
FITCHETT, D. H. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_33 · Cited by 1
Biryukova, E. V., & Kileynikov, D. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-156 · Cited by 1
EFFECTS OF PLANT-BASED DIETS ON CARDIOVASCULAR RISK
Polianska, O. S., Руснак, И., Hulaha, O. I., Horobets, K. V., Кулачек, Я. В., & Москалюк, І. І. (2023) · Реабілітаційні та фізкультурно-рекреаційні аспекти розвитку людини (Rehabilitation & recreation) · doi:10.32782/2522-1795.2023.15.23 · Cited by 1
Chu, J., Lai, Y., Yao, Y., Ye, W., Yao, T., Lin, H., Yuan, D., Ping, F., Zhu, G., Ding, H., et al. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-1160 · Cited by 1
Lin, J., Jiang, Y., Zhou, X., Zhang, T., & Xu, Y. (2024) · Open Chemistry · doi:10.1515/chem-2024-0071 · Cited by 1
Schröder, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030746 · Cited by 1
“Glycemic control Improves glycemic control by reducing glucose reabsorption in the kidneys [89] Improves glycemic control by reducing insulin resistance and increasing insulin sensitivity [58] Oxidative stress Reduces oxidative stress by decreasing ROS production and increasing antioxidant enzymes…”
De-escalation, palliation and end of life care in frail older people with diabetes-a critical review
Siqueira, I., Jenkinson, J., Briggs, P., Picker, H., Chen, X., & Abdelhafiz, A. H. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2535668 · Cited by 1
“In addition, with increasing age and approaching end of life phase, the benefits from hypoglycemic therapy diminish [60].”
Position paper FADOI sulla prevenzione cardiovascolare nei pazienti complessi a rischio
Campanini, G. E. M., Nardi, R., & Pinna, G. (2015) · Italian Journal of Medicine · doi:10.4081/itjm.q.2015.4 · Cited by 1
AGEs drehen maßgeblich an der Atherosklerose-Schraube
Stirban, O. A. (2017) · Info Diabetologie · doi:10.1007/s15034-017-1085-3 · Cited by 1
Neue Antidiabetika und kardiovaskuläre Outcome-Studien
Seufert, J., & Laubner, K. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-121159 · Cited by 1
“[7] Hayward RA, Reaven PD, Wiitala WL et al.”
BackgroundKosiborod, M., & Arnold, S. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00016-9 · Cited by 1
Cardiomyopathie Diabétique: une entité spécifique?
Bounhoure, J., & Michel Komajda, N. (2017) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30528-x · Cited by 1
Risk Factors Management in Diabetic Patients
Kim, S. Y. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.3.157 · Cited by 1
Narne, P. (2019) · Springer eBooks · doi:10.1007/978-981-13-8946-7_18 · Cited by 1
GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact
Breder, I. S. S., & Sposito, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_51 · Cited by 1
Okuyama, H., Sultan, S., Ohara, N., Hamazaki, T., Langsjoen, P. H., Hama, R., Ogushi, Y., Kobayashi, T., Natori, S., Uchino, H., et al. (2021) · MDPI eBooks · doi:10.3390/books978-3-03943-946-1 · Cited by 1
Ambrož, M., de Vries, S. T., Hoogenberg, K., & Denig, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.883103 · Cited by 1
Precision Medicine Approaches for Management of Type 2 Diabetes
Chen, D., Fulcher, J., SCOTT, E. S., & Jenkins, A. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_1 · Cited by 2
Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2
Murphy, E., Cooney, M. T., & McEvoy, J. W. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-16594-8_2 · Cited by 1
Vedin, O. (2015) · Uppsala University Publications (Uppsala University) · Cited by 1
Mortality and metformin use in patients with advanced chronic kidney disease – Authors' reply
Hung, S., Chang, Y., Liu, J., Hsu, C.-C., & Tarng, D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00287-9 · Cited by 1
Is legacy a myth or a reality? We should know, and we do not
Gueyffier, F., & Cucherat, M. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000728 · Cited by 1
“The prolonged follow-up of two more recent trials in type 2 diabetes patients did not show such enthusiastic results, shedding some doubt about the reality of the legacy effect of the antidiabetic drugs [13,14].”
ResultHalimi, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30197-8 · Cited by 1
Evaluation of Berry Extracts on Intestinal Digestive Enzymes and Sugar Transporters
Oh, J. (2017) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · doi:10.7275/10011051 · Cited by 1
Ohkuma, T., Woodward, M., & Chalmers, J. P. (2018) · Diabetes Care · doi:10.2337/dci17-0060 · Cited by 1
“Kawada, intensive glucose-lowering therapy significantly decreased the risk of a composite of major cardiovascular events including heart failure in the Veterans Affairs Diabetes Trial (VADT) (4).”
BackgroundInfluentialKawada, T. (2018) · Diabetes Care · doi:10.2337/dc17-2319 · Cited by 1
“the intensive glucose-lowering intervention showed significant reduction of risk of cardiovascular events, including new or worsening congestive heart failure (5).”
BackgroundRubio-Almanza, M. (2019) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14103.2019.664939 · Cited by 1
Urina-Jassir, M., Herrera-Parra, L. J., Vargas, J. A. H., Valbuena‐Garcia, A. M., Acuña-Merchán, L. A., & Urina‐Triana, M. (2021) · Research Square · doi:10.21203/rs.3.rs-156202/v1 · Cited by 1
Liu, R., Zhang, H., Wang, Q., Xu, Y., Dai, Y., Jiang, S., Jiang, H., & Liu, M. (2024) · Research Square · doi:10.21203/rs.3.rs-3883934/v1 · Cited by 1
S odium‐glucose co‐transporter‐2 inhibitors: A paradigm shift in treatment for type 2 diabetes
Matthews, D. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15963 · Cited by 1
Krempf, M., & Charbonnel, B. H. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30263-7
Variabilité glycémique et hyperglycémie postprandiale : quelle importance au-delà del’HbA1c?
Monnier, L., Colette, C., Wojtusciszyn, A., & Dejager, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30260-1
Effets du contrôle de l’hyperglycémie sur la morbi-mortalité cardiovasculaire (type 1 & type 2)
Vergès, B. L. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30262-5
Wang, J. Y., Leiter, L. A., Langer, A., Tan, M., Goldin, L., Teoh, H., CHENG, A. Y. Y., Connelly, K. A., Goodman, S. G., & Yan, A. T.-K. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.07.070
Auch langfristig ohne überzeugenden Erfolg
Holzgreve, H. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0665-3
Assessing Risks of Glucose Lowering Therapy in Heart Failure: Should We Rely on Post-hoc Analyses?
Hsu, J. J., & Fonarow, G. C. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0486-5
Kardiovaskuläre Effekte von Antidiabetika
Drexel, H., & Scherbaum, W. A. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0089-2
“Allerdings wurde diese sowohl im DCCT [21] als auch in der UKPDS [17] und im VADT [15]nach längerenBeobachtungszeiträumengezeigt.”
BackgroundEnsayos clínicos de resultados de enfermedad cardiovascular en diabetes
Muñoz‐Torres, M., & Muñoz‐Garach, A. (2016) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2016.04.001
Primary and secondary prevention in diabetic patients
Murrone, A., Santucci, A., & Cavallini, C. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000453
Ischemic Heart Disease in Diabetes
Saely, C. H., Vathie, K., & Drexel, H. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch44
Perspectives on medical treatment of type 2 diabetes mellitus
Yoshioka, N. (2017) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.23.015
Pharmacotherapy follow-up in elderly in a public outpatient clinic in Brasilia, Brazil
de Oliveira, M. P. F., & Novaes, M. R. C. G. (2015) · African Journal of Pharmacy and Pharmacology
Tubili, C., Folco, U. D., Nardone, M. R., Tubili, F., & Cohen, O. (2017) · Mediterranean Journal of Nutrition and Metabolism · doi:10.3233/mnm-17141
Découverte d'un diabète de type2 chez un sujetâgé
Bauduceau, B., & Bordier, L. (2017) · doi:10.1016/b978-2-294-74646-8.00003-1
Diabète de type2: antidiabétiques oraux
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00009-2
Diabète de type2: insulinothérapie basale, « flat insulin for flat sugar »
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00012-2
Diabète de type2: initiation de l'insulinothérapie
Bauduceau, B., & Bordier, L. (2017) · doi:10.1016/b978-2-294-74646-8.00016-x
Glycemic control for prevention vascular complication in diabetic patient
Pusparini, P. (2017) · Universa Medicina · doi:10.18051/univmed.2017.v36.77-79
Denk tijdig aan metformine bij diabetes
Jans, N. (2017) · Huisarts en Wetenschap · doi:10.1007/s12445-017-0242-1
Seufert, J., Galle, J.-C., Manning, M., Schmid, V., & Lehrke, M. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-112658
“[15] Hayward RA, Reaven PD, Wiitala WL et al.”
BackgroundDiabétologie: Un antidiabétique oral qui diminue la mortalité
Maitre, S., Portela, M., & Philippé, J. (2015) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2015.02513
Diabetologie: Ein orales Antidiabetikum, das die Mortalität verringert
Maitre, S., Portela, M., & Philippé, J. (2015) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2015.02513
Fisher, M. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch39
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_14-1
Cho, Y., & Kang, E. S. (2018) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2018.7.1.21
Fernández, M. A. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(18)30372-1
VADT (Veterans Affairs Diabetes Trial) : quelles leçons après 15 ans de suivi ?
Charbonnel, B. H. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30178-0
Glycemic Metrics and Targets in Kidney Disease
Neumiller, J. J., & Hirsch, I. B. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_4
The effects of short-term low-carbohydrate and ketogenic interventions on cardiometabolic health
Myette‐Côté, É. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0378478
“Over the past few decades, several groups have investigated the effects of aggressive glucose control on the risk of developing macrovascular complications [144-148].”
BackgroundNew Era of Management for Diabetes and Hypertension
Bando, H. (2018) · Advances in Diabetes & Endocrinology · doi:10.13188/2475-5591.1000009
“At the same time, intensive regimens have not shown a reduction of cardiovascular complications in the long-term [28-32].”
BackgroundThe Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors
Jeon, J. (2019) · Journal of Korean Diabetes · doi:10.4093/jkd.2019.20.2.81
oguno, L. (2019) · Theseus (Ammattikorkeakoulujen)
Im 15 Jahresverlauf kein Legacy-Effekt durch intensive Glukosekontrolle
Fritschka, E. (2019) · Info Diabetologie · doi:10.1007/s15034-019-1569-4
Rábai, M., & Habon, T. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.33
Metadata
- Authors
- Hayward, R. A., Reaven, P. D., Wiitala, W. L., Bahn, G. D., Reda, D. J., Ge, L., McCarren, M., Duckworth, W. C., & Emanuele, N. V.
- Affiliations
- Edward Hines, Jr. VA Hospital (US)
- Phoenix VA Health Care System (US)
- VA Ann Arbor Healthcare System (US)
- Veterans Health Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-04
- Volume
- 372
- Issue
- 23
- Pages
- 2197-2206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153552938
- Cited by
- 668
- References
- 27
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 30 · 2023: 47 · 2022: 28 · 2021: 53 · 2020: 60 · 2019: 77 · 2018: 73 · 2017: 105 · 2016: 113 · 2015: 44
- FWCI
- 97.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs (98‐004)
- Amgen
- AstraZeneca
- Health Services Research and Development
- Novo Nordisk
- National Institutes of Health (98-004)
- National Heart, Lung, and Blood Institute (R01HL067690, R01HL094775)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, HbA1c, major cardiovascular events, cardiovascular mortality, all-cause mortality, military veterans, long-term follow-up, cardiovascular risk reduction, congestive heart failure, amputation, stroke, myocardial infarction, ischemic gangrene
- MeSH terms
- Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Risk, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
